Drug-sensitive FGFR3 mutations in lung adenocarcinoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Lung adenocarcinoma is a leading cause of cancer mortality globally.
• Understanding genetic alterations in diverse populations is crucial for targeted therapies.
• This study focuses on Indian lung adenocarcinoma patients.

Purpose of the Study:

• To identify therapeutically relevant genetic alterations in lung adenocarcinoma of Indian origin.
• To investigate the role of Fibroblast Growth Factor Receptor 3 (FGFR3) mutations.
• To explore FGFR3 as a potential therapeutic target.

Main Methods:

• Sequencing of 676 amplicons in 45 primary lung adenocarcinoma tumors.
• Genotyping of 49 mutations across 23 genes in 363 additional tumors using mass spectrometry.
• In vitro and xenograft mouse models to characterize FGFR3 mutations and inhibitor sensitivity.

Main Results:

• Identified actionable genetic alterations in Indian lung adenocarcinoma.
• FGFR3 mutations found in 5.5% (20/363) of patients.
• FGFR3 mutations were constitutively active, oncogenic, and sensitive to FGFR inhibitors in preclinical models.
• FGFR3 mutations showed a trend toward better survival in younger patients.

Conclusions:

• Presents the first actionable mutation spectrum in Indian lung cancer.
• FGFR3 is implicated as a novel therapeutic target in lung adenocarcinoma.
• These findings may guide personalized treatment strategies for lung cancer patients in India.